Marianne Harris

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. pmc Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
    Marianne Harris
    AIDS Research Program, Providence Health Care Institute, B518 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6 Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    AIDS Res Treat 2012:595762. 2012
  2. ncbi request reprint Barriers to participation in actual HIV vaccine trials
    Shayesta Dhalla
    University of British Columbia, Vancouver, British Columbia, Canada
    Curr HIV Res 11:238-45. 2013
  3. ncbi request reprint Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
    Marianne Harris
    Expert Opin Drug Saf 7:389-400. 2008
  4. doi request reprint Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
    Marianne Harris
    AIDS Research Programme, St Paul s Hospital, Providence Healthcare, Canada
    AIDS 22:1224-6. 2008
  5. ncbi request reprint Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS 20:719-23. 2006
  6. ncbi request reprint Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Antivir Ther 11:79-86. 2006
  7. ncbi request reprint Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
    Julio S G Montaner
    BC Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 38:S73-9. 2004
  8. ncbi request reprint Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3
    Adrienne R Toulson
    BC Centre for Excellence in HIV AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 192:1787-93. 2005
  9. ncbi request reprint Management of HIV-infected patients with multidrug-resistant virus
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care University of British Columbia, 667 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Curr HIV/AIDS Rep 1:116-21. 2004
  10. doi request reprint Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation
    Mark W Hull
    Canadian HIV Trials Network, Vancouver, Canada
    J Clin Pharmacol 49:155-61. 2009

Collaborators

Detail Information

Publications45

  1. pmc Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
    Marianne Harris
    AIDS Research Program, Providence Health Care Institute, B518 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6 Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    AIDS Res Treat 2012:595762. 2012
    ..To continue this trend, the optimal rollout of HAART in both rich and resource-limited settings will require careful planning and strategic use of antiretroviral drugs and monitoring technologies...
  2. ncbi request reprint Barriers to participation in actual HIV vaccine trials
    Shayesta Dhalla
    University of British Columbia, Vancouver, British Columbia, Canada
    Curr HIV Res 11:238-45. 2013
    ..More actual HIV vaccine trials can incorporate questions about and quantify barriers to participation, and this may aid future recruitment strategies. ..
  3. ncbi request reprint Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients
    Marianne Harris
    Expert Opin Drug Saf 7:389-400. 2008
    ..Some antiretroviral therapies have themselves been identified to have clinically significant nephrotoxicity...
  4. doi request reprint Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
    Marianne Harris
    AIDS Research Programme, St Paul s Hospital, Providence Healthcare, Canada
    AIDS 22:1224-6. 2008
    ..The new regimen was well tolerated with no apparent new drug-related adverse clinical or laboratory events...
  5. ncbi request reprint Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS 20:719-23. 2006
    ....
  6. ncbi request reprint Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Antivir Ther 11:79-86. 2006
    ..Mitochondrial nephrotoxicity was investigated as an underlying mechanism. Given the interaction between TDF and didanosine (ddl), their concurrent use was also investigated...
  7. ncbi request reprint Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
    Julio S G Montaner
    BC Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 38:S73-9. 2004
    ..A statistically significant increase in the mtDNA : nDNA ratio was observed after the discontinuation of antiretroviral therapy. Full validation of monitoring the mtDNA : nDNA ratio is currently under way...
  8. ncbi request reprint Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3
    Adrienne R Toulson
    BC Centre for Excellence in HIV AIDS, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 192:1787-93. 2005
    ..The goal of the present study was to characterize outcome and predictors of outcome of treatment interruption (TI) in highly active antiretroviral therapy (HAART)-treated patients...
  9. ncbi request reprint Management of HIV-infected patients with multidrug-resistant virus
    Marianne Harris
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care University of British Columbia, 667 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Curr HIV/AIDS Rep 1:116-21. 2004
    ..Some new drugs are available that may be helpful if used carefully with an active background regimen...
  10. doi request reprint Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation
    Mark W Hull
    Canadian HIV Trials Network, Vancouver, Canada
    J Clin Pharmacol 49:155-61. 2009
    ....
  11. doi request reprint A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population
    Katherine Barraclough
    Division of Nephrology, University of British Columbia, Vancouver, B C, Canada
    Nephron Clin Pract 111:c39-48. 2009
    ..Glomerular filtration rate (GFR) estimation equations have never been validated in the HIV population. This pilot study aimed to compare all currently available methods of kidney function assessment with nuclear GFR in HIV-infected adults...
  12. ncbi request reprint Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy
    Julio S G Montaner
    British Columbia Centrefor Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 34:S85-90. 2003
    ..These results suggest that measurement of this parameter should be investigated as a potential clinical management tool...
  13. pmc Adverse effects of antiretroviral therapy for HIV infection
    Valentina Montessori
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC
    CMAJ 170:229-38. 2004
    ..A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients...
  14. ncbi request reprint Evaluation of treatment tolerability, satisfaction and laboratory parameters in HIV+ patients switching from ritonavir capsule to tablet formulation
    Andy Mtambo
    AIDS Research Program, St Paul s Hospital, Vancouver, BC, Canada
    Curr HIV Res 11:231-7. 2013
    ..This study evaluated treatment satisfaction, gastrointestinal tolerability, depressive symptoms and alterations in laboratory parameters before and after switching from ritonavir capsule to tablet formulation...
  15. ncbi request reprint Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy
    Nelson Lee
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Infect Dis 188:137-41. 2003
    ..Over the short-term, patients receiving MDRT had relatively low mortality. After adjustment for baseline prognostic factors, rates of survival were comparable with those in patients initiating triple-drug ART...
  16. doi request reprint The determinants of poor respiratory health status in adults living with human immunodeficiency virus infection
    Janice M Leung
    1 UBC James Hogg Research Centre, Vancouver, BC, Canada
    AIDS Patient Care STDS 28:240-7. 2014
    ..Limitations of this analysis include the absence of available echocardiograms, diffusion capacity and lung volume testing, and an all-male cohort due to the demographics of the clinic population...
  17. doi request reprint Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma
    Hatoon M Ezzat
    St Paul s Hospital, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 53:2390-6. 2012
    ..Prospective pharmacokinetic studies to devise a rational dosing strategy for vinblastine in patients receiving ritonavir/lopinavir are warranted...
  18. ncbi request reprint Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    Ther Drug Monit 26:516-23. 2004
    ..Evening trough concentrations were the best estimators of the daily nadir; however, no adequate substitute for collecting blood 12 hours postdose emerged from this analysis...
  19. pmc Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
    Silvia A Guillemi
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    J Int AIDS Soc 19:20995. 2016
    ..Tenofovir disoproxil fumarate (TDF)-associated renal dysfunction may abate when TDF is replaced with abacavir (ABC). The extent to which the third drug atazanavir contributes to renal dysfunction is unclear...
  20. doi request reprint Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF
    Marianne Harris
    a British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    HIV Clin Trials . 2017
    ..To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir disoproxil fumarate (TDF)...
  21. ncbi request reprint Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, St Paul s Hospital, Providence Health Care, Vancouver, BC, Canada
    N Engl J Med 346:811-20. 2002
    ..We studied changes in mitochondrial DNA relative to nuclear DNA in the peripheral-blood cells of patients with symptomatic, nucleoside-induced hyperlactatemia...
  22. ncbi request reprint An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR
    Katherine Barraclough
    Department of Nephrology, St Paul s Hospital, Vancouver, British Colombia, V6Z1Y6, Canada
    Nephrol Dial Transplant 22:2391-4. 2007
    ..We support ongoing efforts to develop or refine equations for specific unique and easily identifiable populations...
  23. pmc The bronchial epithelial cell bacterial microbiome and host response in patients infected with human immunodeficiency virus
    Marc A Sze
    Centre for Heart Lung Innovation, St Paul s Hospital and Department of Medicine, University of British Columbia, Rm 166 1081 Burrard St, Vancouver, BC, V6Z 1Y6, Canada
    BMC Pulm Med 16:142. 2016
    ..However, the host response to the lung microbiome is unknown in patients infected with HIV...
  24. pmc Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease
    Joseph C Y Liu
    Centre for Heart Lung Innovation, Vancouver, BC, Canada
    PLoS ONE 10:e0124426. 2015
    ..049). HIV-infected subjects demonstrate advanced cellular aging, yet in a cART-treated cohort, the relationship between aTL and age appears no different from that of HIV-uninfected subjects. ..
  25. ncbi request reprint Efficacy and durability of nevirapine in antiretroviral-experienced patients
    Marianne Harris
    B C Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, 1081 Burrard Street, Vancouver, V6Z 1Y6, Canada
    J Acquir Immune Defic Syndr 34:S53-8. 2003
    ..This paper reviews the clinical data that support the use of NVP in salvage regimens and PI switch strategies...
  26. ncbi request reprint Hepatotoxicity of nucleoside reverse transcriptase inhibitors
    Valentina Montessori
    Clinical Assistant Professor, University of British Columbia, Vancouver, Canada
    Semin Liver Dis 23:167-72. 2003
    ..Early recognition and intervention are essential to avert serious outcomes...
  27. doi request reprint Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population
    Silvia Guillemi
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Clin Densitom 13:456-61. 2010
    ..Lower BMI was independently associated with low BMD. No correlation was found between abnormal BMD and cumulative exposure to any antiretroviral agents...
  28. pmc Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia
    Helene C F Cote
    Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada
    PLoS ONE 7:e39266. 2012
    ..We therefore investigated whether in utero or childhood exposure to NRTIs affects leukocyte telomere length (LTL), a marker of cellular aging...
  29. doi request reprint Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort
    A M Cescon
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    HIV Med 12:352-60. 2011
    ..The aim of the study was to evaluate time to virological suppression in a cohort of individuals who started highly active antiretroviral therapy (HAART), and to explore the factors associated with suppression...
  30. ncbi request reprint Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens
    Natasha Press
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital and Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    HIV Clin Trials 3:17-20. 2002
    ..By potentiating the activity of abacavir, MMF may improve antiviral efficacy. However, it may also lead to myelosuppression, such as was seen in patients taking hydroxyurea-containing regimens...
  31. ncbi request reprint Management of HIV-infected Patients with Multidrug-resistant Virus
    Julio S G Montaner
    University of British Columbia St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada
    Curr Infect Dis Rep 4:259-265. 2002
    ..The potential roles of newer agents, adjuvants, treatment interruptions, and immune-based therapies remain under investigation...
  32. ncbi request reprint Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol
    Lena Normén
    Canadian HIV Trials Network, Pacific Region, Vancouver, British Columbia, Canada
    Diabetes Care 27:2241-2. 2004
  33. pmc Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
    Kimberley L S Ambler
    Division of Hematology, University of British Columbia, 2775 Laurel Street, Vancouver, BC, Canada V5Z 1M9
    Adv Hematol 2012:910954. 2012
    ..Although most patients achieved a safe platelet count with primary ITP treatment, nearly all required retreatment for ITP recurrence. New approaches to the treatment of severe ITP in this population are needed...
  34. ncbi request reprint Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient
    Rafael de la Rosa
    AIDS 18:578-9. 2004
  35. ncbi request reprint Transient neuropathy after needle-free injection outside of recommended sites
    Marianne Harris
    AIDS 20:784-5. 2006
  36. ncbi request reprint Stopping antiretroviral therapy: easier said than done
    Mark Hull
    AIDS 21:1817-8. 2007
  37. ncbi request reprint Intracellular carbovir triphosphate levels in patients taking abacavir once a day
    Marianne Harris
    AIDS 16:1196-7. 2002
  38. ncbi request reprint Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy
    Alicja M Tesiorowski
    J Acquir Immune Defic Syndr 31:250-1. 2002
  39. ncbi request reprint Random venous lactate levels among HIV-positive patients on antiretroviral therapy
    Marianne Harris
    J Acquir Immune Defic Syndr 31:448-50. 2002
  40. doi request reprint Exacerbation of depression associated with starting raltegravir: a report of four cases
    Marianne Harris
    AIDS 22:1890-2. 2008
  41. ncbi request reprint Venous and arterial blood lactate in HIV-infected patients
    Carlos Zala
    Antivir Ther 7:309-10. 2002
  42. ncbi request reprint Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients
    Janet M Raboud
    Department of Public Health Sciences and Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada
    AIDS 16:1627-32. 2002
    ..To describe the characteristics and predictors of transient plasma viral load (pVL) rebounds among patients on stable antiretroviral therapy and to determine the effect of one or more pVL rebounds on virological response at week 52...
  43. ncbi request reprint Structured treatment interruptions: a risky business
    Julio Montaner
    Clin Infect Dis 40:601-3. 2005
  44. doi request reprint Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia
    Naoufel Azizi
    Laboratoire de Virologie Moleculaire, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    J Gen Virol 89:1716-28. 2008
    ..24) or CIN-1 (5 of 14, P=0.50). HPV-16 E2 polymorphism was a significant factor that influenced measures of HPV-16 integrated viral load...
  45. ncbi request reprint Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors
    Marianne Harris
    AIDS 16:798-9. 2002